An analysis of 5,519 men undergoing biopsy in the control arm of the Prostate Cancer Prevention Trial uncovered no evidence to support the recommendation that men with high PSA velocity be biopsied in the absence of other indications, according to an online report in the Journal of the National Cancer Institute.
Researchers Andrew J. Vickers, PhD, of the Department of Epidemiology and Biostatistics at Memorial Sloan-Kettering Cancer Center in New York, and colleagues contend that this measure should not be included in practice guidelines, contrary to National Comprehensive Cancer Network and American Urological Association recommendations. Study results indicated that PSA level alone was a much better predictor of biopsy outcome than PSA velocity.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.